T-Cell Therapy: Options for Infectious Diseases

Clinical Infectious Diseases

Volumn 61, Issue , 2015, Pages S217-S224

  Parida, Shreemanta K ^a   Poiret, Thomas ^a,b   Zhenjiang, Liu ^a   Meng, Qingda ^a   Heyckendorf, Jan ^c   Lange, Christoph ^a,c,d   Ambati, Aditya S ^a,b   Rao, Martin V ^a   Valentini, Davide ^a,b   Ferrara, Giovanni ^a   Rangelova, Elena ^e   Dodoo, Ernest ^a,b   Zumla, Alimuddin ^f,g   Maeurer, Markus ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Division of Clinical Infectious Diseases German Center for Infection Research Research Center Borstel   (United States)

^d UNIVERSITY OF LÜBECK   (Germany)

^e Division of Surgery   (United States)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

adoptive cell therapy; CAR; host directed therapy; Mtb; T cells

Indexed keywords

ALPHA INTERFERON; CD1 ANTIGEN; CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; DECTIN 1; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR 1; GRANULOCYTE COLONY STIMULATING FACTOR; HLA DP ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; T LYMPHOCYTE RECEPTOR; CYTOKINE; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CROSS REACTION; CYTOKINE PRODUCTION; DONOR LYMPHOCYTE INFUSION; DRUG RESISTANT TUBERCULOSIS; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE EXPRESSION; GRAFT RECIPIENT; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNITY; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INFECTION; LONG TERM MEMORY; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY T LYMPHOCYTE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATIENT SAFETY; PRIMARY INFECTION; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE; T LYMPHOCYTE CELL THERAPY; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; WNT SIGNALING PATHWAY; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; IMMUNOLOGY; TRANSPLANTATION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADOPTIVE TRANSFER; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; IMMUNITY, CELLULAR; MYCOBACTERIUM TUBERCULOSIS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84943409072     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ615     Document Type: Article

References (74)

1. World Health Organization. Global tuberculosis report 2014. Geneva, Switzerland: WHO, 2014.
2. Parida SK, Axelsson-Robertson R, Rao MV, et al. Totally drug-resistant tuberculosis and adjunct therapies. J Intern Med 2015; 277:388-405.
3. TB Alliance. Pipeline of TB drugs. Available at: http://www.tballiance.org/pipeline/pipeline.php. Accessed 8 May 2015.
4. Zumla A, Chakaya J, Centis R, et al. Tuberculosis treatment and management-an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respir Med 2015; 3:220-34.
5. Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS One 2011; 6:e17601.
6. Jasenosky LD, Scriba TJ, HanekomWA, Goldfeld AE. T cells and adaptive immunity to Mycobacterium tuberculosis in humans. Immunol Rev 2015; 264:74-87.
7. Abel L, El-Baghdadi J, Bousfiha AA, Casanova JL, Schurr E. Human genetics of tuberculosis: a long and winding road. Philos Trans R Soc Lond B Biol Sci 2014; 369:20130428.
8. Doffinger R, Dupuis S, Picard C, et al. Inherited disorders of IL-12-and IFNgamma-mediated immunity: a molecular genetics update. Mol Immunol 2002; 38:903-9.
9. Jouanguy E, Altare F, Lamhamedi S, et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N Engl J Med 1996; 335:1956-61.
10. Casanova JL, Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol 2002; 20:581-620.
11. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56:731-40.
12. Bruns H, Meinken C, Schauenberg P, et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009; 119:1167-77.
13. Day CL, Moshi ND, Abrahams DA, et al. Patients with tuberculosis disease have Mycobacterium tuberculosis-specific CD8T cells with a proapoptotic phenotype and impaired proliferative capacity, which is not restored following treatment. PLoS One 2014; 9:e94949.
14. Prezzemolo T, Guggino G, La Manna MP, Di Liberto D, Dieli F, Caccamo N. Functional signatures of human CD4 and CD8T cell responses to Mycobacterium tuberculosis. Front Immunol 2014; 5:180.
15. Spada FM, Grant EP, Peters PJ, et al. Self-recognition of CD1 by gamma/delta T cells: implications for innate immunity. J Exp Med 2000; 191:937-48.
16. Mihret A, Mamo G, Tafesse M, Hailu A, Parida S. Dendritic cells activate and mature after infection with Mycobacterium tuberculosis. BMC Res Notes 2011; 4:247.
17. Kim K, Perera R, Tan DB, et al. Circulating mycobacterial-reactive CD4+ T cells with an immunosuppressive phenotype are higher in active tuberculosis than latent tuberculosis infection. Tuberculosis 2014; 94:494-501.
18. Singh A, Dey AB, Mohan A, Mitra DK. Programmed death-1 receptor suppresses gamma-IFN producing NKT cells in human tuberculosis. Tuberculosis 2014; 94:197-206.
19. Arora P, Foster EL, Porcelli SA. CD1d and natural killer T cells in immunity to Mycobacterium tuberculosis. Adv Exp Med Biol 2013; 783:199-223.
20. Gold MC, Napier RJ, Lewinsohn DM. MR1-restricted mucosal associated invariant T (MAIT) cells in the immune response to Mycobacterium tuberculosis. Immunol Rev 2015; 264:154-66.
21. van Meijgaarden KE, Haks MC, Caccamo N, Dieli F, Ottenhoff TH, Joosten SA. Human CD8+ T-cells recognizing peptides from Mycobacterium tuberculosis (Mtb) presented by HLA-E have an unorthodox Th2-like, multifunctional, Mtb inhibitory phenotype and represent a novel human T-cell subset. PLoS Pathog 2015; 11:e1004671.
22. Munoz L, Casas S, Juanola X, et al. Prevention of anti-tumor necrosis factor-associated tuberculosis: a 10-year longitudinal cohort study. Clin Infect Dis 2015; 60:349-56.
23. Lugli E, Dominguez MH, Gattinoni L, et al. Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest 2013; 123:594-9.
24. Biasco L, Scala S, Basso Ricci L, et al. In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells. Sci Transl Med 2015; 7:273-13.
25. Cieri N, Oliveira G, Greco R, et al. Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation. Blood 2015; 125:2865-74.
26. Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011; 17:1290-7.
27. van der Waart AB, van de Weem NM, Maas F, et al. Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy. Blood 2014; 124:3490-500.
28. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; 124: 188-95.
29. Vinh DC. Cytokine immunomodulation for the treatment of infectious diseases: lessons from primary immunodeficiencies. Expert Rev Clin Immunol 2014; 10:1069-100.
30. Dvorak CC, Gilman AL, Horn B, et al. Clinical and immunologic outcomes following haplocompatible donor lymphocyte infusions. Bone Marrow Transplant 2009; 44:805-12.
31. Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute LeukemiaWorking Party. J Clin Oncol 2007; 25:4938-45.
32. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330:1185-91.
33. Loren AW, Porter DL. Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation. Curr Opin Oncol 2006; 18:107-14.
34. Amrolia PJ, Rao K, Slater O, Ramsay A, Veys PA, Webb DK. Fatal graft-versus-host disease following HLA-mismatched donor lymphocyte infusion. Bone Marrow Transplant 2001; 28:623-5.
35. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992; 257:238-41.
36. Fan WC, Liu CJ, Hong YC, et al. Long-term risk of tuberculosis in haematopoietic stem cell transplant recipients: a 10-year nationwide study. Int J Tuberc Lung Dis 2015; 19:58-64.
37. Sester M, van Leth F, Bruchfeld J, et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med 2014; 190:1168-76.
38. Hausmann S, Martin M, Gauthier L, Wucherpfennig KW. Structural features of autoreactive TCR that determine the degree of degeneracy in peptide recognition. J Immunol 1999; 162:338-44.
39. Mitsuyasu RT, Anton PA, Deeks SG, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virusinfected subjects. Blood 2000; 96:785-93.
40. Deeks SG, Wagner B, Anton PA, et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 2002; 5:788-97.
41. Scholler J, Brady TL, Binder-Scholl G, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012; 4:132ra53.
42. Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118:4817-28.
43. Deniger DC, Moyes JS, Cooper LJ. Clinical applications of gamma delta T cells with multivalent immunity. Front Immunol 2014; 5:636.
44. Deniger DC, Switzer K,Mi T, et al. Bispecific T-cells expressing polyclonal repertoire of endogenous gammadelta T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther 2013; 21:638-47.
45. Kumaresan PR, Manuri PR, Albert ND, et al. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci USA 2014; 111:10660-5.
46. Joseph A, Zheng JH, Follenzi A, et al. Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity. J Virol 2008; 82:3078-89.
47. Zhao Y, Zheng Z, Cohen CJ, et al. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol Ther 2006; 13:151-9.
48. Aronovich EL, McIvor RS, Hackett PB. The Sleeping Beauty transposon system: a non-viral vector for gene therapy. Hum Mol Genet 2011; 20: R14-20.
49. Axelsson-Robertson R, Magalhaes I, Parida SK, Zumla A, Maeurer M. The immunological footprint of Mycobacterium tuberculosis T-cell epitope recognition. J Infect Dis 2012; 205(suppl 2):S301-15.
50. Robbins PF, Kassim SH, Tran TL, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: longterm follow-up and correlates with response. Clin Cancer Res 2015; 21:1019-27.
51. Straetemans T, van Brakel M, van Steenbergen S, et al. TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanomaspecific immune targets. Clin Dev Immunol 2012; doi:10.1155/2012/586314.
52. Morgan RA, Chinnasamy N, Abate-Daga D, et al. Cancer regression and neurological toxicity following anti-MAGE-A3TCR gene therapy. J Immunother 2013; 36:133-51.
53. Comas I, Chakravartti J, Small PM, et al. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat Gen 2010; 42:498-503.
54. Lindestam Arlehamn CS, Paul S, Mele F, et al. Immunological consequences of intragenus conservation of Mycobacterium tuberculosis T-cell epitopes. Proc Natl Acad Sci USA 2015; 112:E147-55.
55. Felio K, Nguyen H, Dascher CC, et al. CD1-restricted adaptive immune responses to mycobacteria in human group 1 CD1 transgenic mice. J Exp Med 2009; 206:2497-509.
56. Gold MC, McLaren JE, Reistetter JA, et al. MR1-restricted MAIT cells display ligand discrimination and pathogen selectivity through distinct T cell receptor usage. J Exp Med 2014; 211:1601-10.
57. Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci USA 2001; 98:3964-9.
58. Matsuzaki J, Tsuji T, Luescher I, et al. Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells. Can Immunol Res 2014; 2:341-50.
59. Molloy PE, Sewell AK, Jakobsen BK. Soluble T cell receptors: novel immunotherapies. Curr Opin Pharmacol 2005; 5:438-43.
60. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550-7.
61. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015; 348:62-8.
62. Axelsson-Robertson R, Loxton AG,Walzl G, et al. A broad profile of codominant epitopes shapes the peripheral Mycobacterium tuberculosis specific CD8+ T-cell immune response in South African patients with active tuberculosis. PLoS One 2013; 8:e58309.
63. Zhao J, Cao Y, Lei Z, Yang Z, Zhang B, Huang B. Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res 2010; 70:4850-8.
64. Wang J, Yin Y, Wang X, et al. Ratio of monocytes to lymphocytes in peripheral blood in patients diagnosed with active tuberculosis. Braz J Infect Dis 2015; 19:125-31.
65. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95:190-8.
66. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725-33.
67. Jin Y, Xia M, Saylor CM, et al. Cutting edge: intrinsic programming of thymic gammadeltaT cells for specific peripheral tissue localization. J Immunol 2010; 185:7156-60.
68. Dechanet J, Merville P, Berge F, et al. Major expansion of gammadelta T lymphocytes following cytomegalovirus infection in kidney allograft recipients. J Infect Dis 1999; 179:1-8.
69. Fujishima N, Hirokawa M, Fujishima M, et al. Skewed T cell receptor repertoire of Vdelta1(+) gammadelta T lymphocytes after human allogeneic haematopoietic stem cell transplantation and the potential role for Epstein-Barr virus-infected B cells in clonal restriction. Clin Exp Immunol 2007; 149:70-9.
70. Chen CY, Yao S, Huang D, et al. Phosphoantigen/IL2 expansion and differentiation of Vgamma2Vdelta2T cells increase resistance to tuberculosis in nonhuman primates. PLoS Pathog 2013; 9:e1003501.
71. Sakamoto M, Nakajima J, Murakawa T, et al. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded gammadeltaTcells: a phase I clinical study. J Immunother 2011; 34: 202-11.
72. Kobayashi H, Tanaka Y, Shimmura H, Minato N, Tanabe K. Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma. Anticancer Res 2010; 30:575-9.
73. Pooran A, Pieterson E, Davids M, Theron G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa PLoS One 2013; 8:e54587.
74. Diel R, Vandeputte J, de Vries G, Stillo J,Wanlin M, Nienhaus A. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Eur Respir J 2014; 43:554-65.